This article was originally published in Start Up
CryoCor Inc. is using cryoblation to cure atrial fibrillation. The company believes its approach is safer and more effective than radio-frequency based ablation, particularly for a-fib originating in pulmonary veins.
You may also be interested in...
Despite widespread and increasing prevalence, atrial fibrillation has frustrated clinicians, device companies, and investors, resulting in only a small number of doctors treating a small number of patients. Ablation Frontiers believes its system will finally enable many more doctors to treat all types of AF patients because it is developing products and procedures that are simpler for doctors to use and perform, finally providing a broad-based solution to this rapidly growing market.
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.